title: Cholesterol is essential for macrophage inflammatory protein 1 beta binding and conformational integrity of CC chemokine receptor 5.
abstract: The chemokine receptor, CCR5, is used as a human immunodeficiency virus coreceptor in combination with CD4 during transmission and early infection. CCR5 has been shown to be palmitoylated and targeted to cholesterol- and sphingolipid-rich membrane microdomains termed "lipid rafts." However, the role of cholesterol and lipid rafts on chemokine binding and signaling through CCR5 remains unknown. We found that cholesterol extraction by hydroxypropyl-beta-cyclodextrin (BCD) significantly reduced the binding and signaling of macrophage inflammatory protein 1 beta (MIP-1 beta) using CCR5-expressing CEM-NKR T cells. Reloading treated cells with cholesterol but not 4-cholesten-3-one, an oxidized form of cholesterol, restored MIP-1 beta binding to BCD-treated cells. Antibodies specific for distinct CCR5 epitopes lost their ability to bind to the cell surface after cholesterol extraction to varying degrees. Moreover, cells stained with fluorescently labeled MIP-1 beta extensively colocalized with the GM1 lipid raft marker while using anti-CCR5 antibodies; most of CCR5 on these cells only partially colocalized with GM1, suggesting that active ligand binding facilitates receptor association with lipid rafts or that raft association promotes a higher affinity conformation of CCR5. Together, these data demonstrate that cholesterol and lipid rafts are important for the maintenance of the CCR5 conformation and are necessary for both the binding and function of this chemokine receptor.
authors.affiliation: Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
authors.forename: Dzung H
authors.initials: DH
authors.lastname: Nguyen
authors.forename: Dennis
authors.initials: D
authors.lastname: Taub
mesh_terms: D000073738:2-Hydroxypropyl-beta-cyclodextrin; D020013:Calcium Signaling / Q000187:drug effects; D054407:Chemokine CCL4; D002784:Cholesterol / Q000494:pharmacology* / Q000502:physiology; D003505:Cyclodextrins / Q000494:pharmacology; D005079:Excipients / Q000494:pharmacology; D006801:Humans; D019402:Macrophage Inflammatory Proteins / Q000378:metabolism*; D021962:Membrane Microdomains / Q000502:physiology; D011485:Protein Binding / Q000187:drug effects; D011487:Protein Conformation / Q000187:drug effects; D019713:Receptors, CCR5 / Q000737:chemistry / Q000378:metabolism*; D013601:T-Lymphocytes / Q000737:chemistry / Q000378:metabolism; D014407:Tumor Cells, Cultured; D047392:beta-Cyclodextrins
chemical_list: D054407:Chemokine CCL4; D003505:Cyclodextrins; D005079:Excipients; D019402:Macrophage Inflammatory Proteins; D019713:Receptors, CCR5; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D002784:Cholesterol